-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7

Benzinga·05/15/2026 17:03:54
Listen to the news
B. Riley Securities analyst William Woods maintains Aardvark Therapeutics (NASDAQ:AARD) with a Buy and lowers the price target from $8 to $7.